Why is there so much therapy-related AML and MDS and so little therapy-related CML?

Leuk Res. 2014 Oct;38(10):1162-4. doi: 10.1016/j.leukres.2014.08.002. Epub 2014 Aug 11.

Authors

Robert Peter Gale¹, Lynn Hlatky², Rainer K Sachs³, Tomas Radivoyevitch⁴

Affiliations

¹ Haematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, UK. Electronic address: robertpetergale@gmail.com.
² Center of Cancer Systems Biology, GRI, Tufts University School of Medicine, Boston, MA, United States.
³ Department of Mathematics and Physics, University of California, Berkeley, CA, United States.
⁴ Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH, United States.

PMID: 25175829
DOI: 10.1016/j.leukres.2014.08.002

No abstract available

Keywords: DNA-damaging drugs; Radiation; Secondary leukemia; Therapy-related leukemia.

Publication types

Editorial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

Antineoplastic Agents / adverse effects*
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / epidemiology*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
Leukemia, Myeloid, Acute / epidemiology
Leukemia, Myeloid, Acute / etiology*
Leukemia, Myeloid, Acute / genetics
Leukemia, Radiation-Induced / epidemiology
Leukemia, Radiation-Induced / etiology*
Leukemia, Radiation-Induced / genetics
Myelodysplastic Syndromes / epidemiology
Myelodysplastic Syndromes / etiology*
Myelodysplastic Syndromes / genetics
Neoplasms, Second Primary / chemically induced*
Neoplasms, Second Primary / epidemiology
Neoplasms, Second Primary / genetics

Substances

Antineoplastic Agents

Grants and funding